US FDA Sets Goal For Biosimilar, Drug Promotion Guidances

The US Food and Drug Administration's drug center plans to issue 102 new and revised draft guidances during calendar year 2016, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and abbreviated new drug application (ANDA) refuse-to-receive standards.

The US Food and Drug Administration's drug center plans to issue 102 new and revised draft guidances during calendar year 2016, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and abbreviated new drug application (ANDA) refuse-to-receive standards.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet